Last CNY21.11 CNY
Change Today +0.01 / 0.05%
Volume 2.7M
002399 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 3:00 AM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

shenzhen hepalink pharmace-a (002399) Snapshot

Open
CNY21.10
Previous Close
CNY21.10
Day High
CNY21.25
Day Low
CNY21.00
52 Week High
02/27/14 - CNY23.50
52 Week Low
09/2/13 - CNY18.10
Market Cap
16.9B
Average Volume 10 Days
4.5M
EPS TTM
CNY0.31
Shares Outstanding
800.2M
EX-Date
06/9/14
P/E TM
67.9x
Dividend
CNY0.30
Dividend Yield
1.42%
Current Stock Chart for SHENZHEN HEPALINK PHARMACE-A (002399)

Related News

No related news articles were found.

shenzhen hepalink pharmace-a (002399) Related Businessweek News

No Related Businessweek News Found

shenzhen hepalink pharmace-a (002399) Details

Shenzhen Hepalink Pharmaceutical Co., Ltd. researches and develops, produces, and sells heparin sodium API and heparin derivatives to pharmaceutical companies in China and internationally. It offers Heparin sodium for blood clotting. The company was founded in 1998 and is headquartered in Shenzhen, China.

Founded in 1998

shenzhen hepalink pharmace-a (002399) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

shenzhen hepalink pharmace-a (002399) Key Developments

Shenzhen Hepalink Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Jul 28, 2014

Shenzhen Hepalink Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Jul 28, 2014., at 14:00 China Standard Time. Agenda: To consider the implementation of employee stock ownership plan via money borrowing by employees; and to consider the authorization to the board to handle matters in relation to employee stock ownership plan.

Shenzhen Hepalink Pharmaceutical Co., Ltd. to Report Q1, 2014 Results on Jul 31, 2014

Shenzhen Hepalink Pharmaceutical Co., Ltd. announced that they will report Q1, 2014 results on Jul 31, 2014

Shenzhen Hepalink Pharmaceutical Co., Ltd. Elects Zhang Rongqing as Independent Director; Approves Profit Distribution Plan for the Year 2013

Shenzhen Hepalink Pharmaceutical Co., Ltd. announced that its shareholders at the Annual General Meeting held on May 16, 2014 elected Zhang Rongqing as independent director. The shareholders at the Annual General Meeting approved tax included cash dividend of CNY 3.00 per 10 share for the year 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002399:CH CNY21.11 CNY +0.01

002399 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002399.
View Industry Companies
 

Industry Analysis

002399

Industry Average

Valuation 002399 Industry Range
Price/Earnings 90.8x
Price/Sales 11.7x
Price/Book -- Not Meaningful
Price/Cash Flow 91.2x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHENZHEN HEPALINK PHARMACE-A, please visit www.hepalink.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.